Top

Published in:

Open Access 01-12-2023 | Buprenorphine | Research

Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature

Authors: Andrea Jakubowski, Sabrina Fowler, Aaron D. Fox

Published in: Addiction Science & Clinical Practice | Issue 1/2023

Abstract

Background

Syringe services programs (SSPs) provide a spectrum of health services to people who use drugs, with many providing referral and linkage to substance use disorder (SUD) treatment, and some offering co-located treatment with medications for opioid use disorder (MOUD). The objective of this study was to review the evidence for SSPs as an entry point for SUD treatment with particular attention to co-located (onsite) MOUD.

Methods

We performed a scoping review of the literature on SUD treatment for SSP participants. Our initial query in PubMed led to title and abstract screening of 3587 articles, followed by full text review of 173, leading to a final total of 51 relevant articles. Most articles fell into four categories: (1) description of SSP participants’ SUD treatment utilization; (2) interventions to link SSP participants to SUD treatment; (3) post-linkage SUD treatment outcomes; (4) onsite MOUD at SSPs.

Results

SSP participation is associated with entering SUD treatment. Barriers to treatment entry for SSP participants include: use of stimulants, lack of health insurance, residing far from treatment programs, lack of available appointments, and work or childcare responsibilities. A small number of clinical trials demonstrate that two interventions (motivational enhancement therapy with financial incentives and strength-based case management) are effective for linking SSP participants to MOUD or any SUD treatment. SSP participants who initiate MOUD reduce their substance use, risk behaviors, and have moderate retention in treatment. An increasing number of SSPs across the United States offer onsite buprenorphine treatment, and a number of single-site studies demonstrate that patients who initiate buprenorphine treatment at SSPs reduce opioid use, risk behaviors, and have similar retention in treatment to patients in office-based treatment programs.

Conclusions

SSPs can successfully refer participants to SUD treatment and deliver onsite buprenorphine treatment. Future studies should explore strategies to optimize the implementation of onsite buprenorphine. Because linkage rates were suboptimal for methadone, offering onsite methadone treatment at SSPs may be an appealing solution, but would require changes in federal regulations. In tandem with continuing to develop onsite treatment capacity, funding should support evidence-based linkage interventions and increasing accessibility, availability, affordability and acceptability of SUD treatment programs.

Available only for authorised users

Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.PubMedPubMedCentralCrossRef

Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.PubMedCrossRef

Lambdin BH, Bluthenthal RN, Wenger LD, Wheeler E, Garner B, Lakosky P, et al. Overdose education and naloxone distribution within syringe service programs—United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1117–21.PubMedPubMedCentralCrossRef

McNeil R, Small W. “Safer environment interventions”: a qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014;106:151–8.PubMedPubMedCentralCrossRef

NASEN. North American Syringe Exchange Network|NASEN. https://nasen.org. Accessed 21 Dec 2022.

Jones CM. Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S. Int J Drug Policy. 2019;70:22–32. https://doi.org/10.1016/j.drugpo.2019.04.006.CrossRefPubMed

Behrends CN, Kapadia SN, Schackman BR, Frimpong JA. Addressing barriers to on-site HIV and HCV testing services in methadone maintenance treatment programs in the United States. J Public Heal Manag Pract. 2020. https://doi.org/10.1097/PHH.0000000000001262.CrossRef

Behrends CN, Lu X, Corry GJ, LaKosky P, Prohaska SM, Glick SN, et al. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. Drug Alcohol Depend. 2022;232:109323.PubMedPubMedCentralCrossRef

Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: Philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119:32–9.PubMedPubMedCentralCrossRef

10.

Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198(Oct 2018):80–6. https://doi.org/10.1016/j.drugalcdep.2019.01.037.CrossRefPubMedPubMedCentral

11.

Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(48):1337–41.PubMedCrossRef

12.

Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D. Drug abuse treatment success among needle exchange participants. Public Heal Rep. 1998;113(Suppl 1):129–39.

13.

Bartholomew TS, Onugha J, Bullock C, Scaramutti C, Patel H, Forrest DW, et al. Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL. Harm Reduct J. 2020;17(1):1–8.CrossRef

14.

Macneil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Drug Alcohol Rev. 2011;30(1):26–32.PubMedCrossRef

15.

National Harm Reduction Coalition. Principles of Harm Reduction. 2020. https://harmreduction.org/about-us/principles-of-harm-reduction/. Accessed 6 Apr 2019.

16.

Fox AD, Chamberlain A, Frost T, Cunningham CO. Harm reduction agencies as a potential site for buprenorphine treatment. Subst Abus. 2015;36(2):155–60.PubMedPubMedCentralCrossRef

17.

Strike C, Miskovic M. Scoping out the literature on mobile needle and syringe programs-review of service delivery and client characteristics, operation, utilization, referrals, and impact. Harm Reduct J. 2018;15(1):6.PubMedPubMedCentralCrossRef

18.

Kidorf M, King VL. Expanding the public health benefits of syringe exchange programs. Can J Psychiatry. 2008;53(8):487–95.PubMedCrossRef

19.

Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):1–7.CrossRef

20.

21.

Andraka-Christou B, Randall-Kosich O, Totaram R. Designing an “ideal” substance use disorder treatment center: perspectives of people who have utilized medications for opioid use disorder. Qual Heal Res. 2021;31(3):512–22.CrossRef

22.

Sohler NL, Weiss L, Egan JE, López CM, Favaro J, Cordero R, et al. Consumer attitudes about opioid addiction treatment: a focus group study in New York City. J Opioid Manag. 2013;9(2):111–9.PubMedPubMedCentralCrossRef

23.

Carvell AM, Hart GJ. Help-seeking and referrals in a needle exchange: a comprehensive service to injecting drug users. Br J Addict. 1990;85(2):235–40.PubMedCrossRef

24.

Riley ED, Safaeian M, Strathdee SA, Brooner RK, Beilenson P, Vlahov D. Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse. 2002;37(14):1869–86.PubMedCrossRef

25.

Gervasoni JP, Balthasar H, Huissoud T, Jeannin A, Dubois-Arber F. A high proportion of users of low-threshold facilities with needle exchange programmes in Switzerland are currently on methadone treatment: implications for new approaches in harm reduction and care. Int J Drug Policy. 2012;23(1):33–6.PubMedCrossRef

26.

Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abus Treat. 2000;19(3):247–52.CrossRef

27.

Latkin CA, Davey MA, Hua W. Needle exchange program utilization and entry into drug user treatment: is there a long-term connection in Baltimore, Maryland? Subst Use Misuse. 2006;41(14):1991–2001.PubMedCrossRef

28.

Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? J Subst Abus Treat. 1998;15(3):183–91.CrossRef

29.

Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis VA, Macalino G, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Heal. 1999;76(4):448–60.CrossRef

30.

Deering KN, Kerr T, Tyndall MW, Montaner JS, Gibson K, Irons L, et al. A peer-led mobile outreach program and increased utilization of detoxification and residential drug treatment among female sex workers who use drugs in a Canadian setting. Drug Alcohol Depend. 2011;113(1):46–54.PubMedCrossRef

31.

Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Heal. 2003;80(3):416–27.CrossRef

32.

Surratt HL, Otachi JK, Williams T, Gulley J, Lockard AS, Rains R. Motivation to change and treatment participation among syringe service program utilizers in rural Kentucky. J Rural Heal. 2020;36(2):224–33.CrossRef

33.

Porter J, Metzger D, Scotti R. Bridge to services: drug injectors’ awareness and utilization of drug user treatment and social service referrals, medical care, and HIV testing provided by needle exchange programs. Subst Use Misuse. 2002;37(11):1305–30.PubMedCrossRef

34.

Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat. 2015;48(1):112–6. https://doi.org/10.1016/j.jsat.2014.07.015.CrossRefPubMed

35.

Kidorf M, King VL, Neufeld K, Peirce J, Kolodner K, Brooner RK. Improving substance abuse treatment enrollment in community syringe exchangers. Addiction. 2009. https://doi.org/10.1111/j.1360-0443.2009.02560.x.CrossRefPubMed

36.

Kidorf M, Disney E, King V, Kolodner K, Beilenson P, Brooner RK. Challenges in motivating treatment enrollment in community syringe exchange participants. J Urban Heal Bull New York Acad Med. 2005;82(3):456.

37.

Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225–32.PubMedCrossRef

38.

Kidorf M, King VL, Peirce J, Kolodner K, Brooner RK. A treatment reengagement intervention for syringe exchangers. J Subst Abus Treat. 2011;41(4):415–21.CrossRef

39.

Kidorf M, King VL, Gandotra N, Kolodner K, Brooner RK. Improving treatment enrollment and re-enrollment rates of syringe exchangers: 12-month outcomes. Drug Alcohol Depend. 2012;124(1–2):162–6.PubMedCrossRef

40.

Bråbäck M, Nilsson S, Isendahl P, Troberg K, Brådvik L, Håkansson A. Malmö Treatment Referral and Intervention Study (MATRIS)—effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. Addiction. 2016;111(5):866–73.PubMedCrossRef

41.

Fox AD, Sohler NL, Frost T, Lopez C, Cunningham CO. Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduct J. 2017;14(1):23.PubMedPubMedCentralCrossRef

42.

Kidorf M, Brooner RK, Leoutsakos JM, Peirce J. Treatment initiation strategies for syringe exchange referrals to methadone maintenance: a randomized clinical trial. Drug Alcohol Depend. 2018;187:343–50.PubMedCrossRef

43.

Bråbäck M, Ekström L, Troberg K, Nilsson S, Isendahl P, Brådvik L, et al. Malmö treatment referral and intervention study-high 12-month retention rates in patients referred from syringe exchange to methadone or buprenorphine/naloxone treatment. Front Psychiatry. 2017;8:161.PubMedPubMedCentralCrossRef

44.

Havens JR, Cornelius LJ, Ricketts EP, Latkin CA, Bishai D, Lloyd JJ, et al. The effect of a case management intervention on drug treatment entry among treatment-seeking injection drug users with and without comorbid antisocial personality disorder. J Urban Heal. 2007;84(2):267–71.CrossRef

45.

Kidorf M, Brooner RK, Leoutsakos JM, Peirce J. Reducing risky drug use behaviors by enrolling syringe exchange registrants in methadone maintenance. Subst Use Misuse. 2021;56(4):546–51.PubMedCrossRef

46.

Kidorf M, Brooner RK, Yan H, Peirce J. Sexual-risk reduction following the referral of syringe exchange registrants to methadone maintenance: impact of gender and drug use. J Subst Abus Treat. 2021;124:108286.CrossRef

47.

Neufeld K, King V, Peirce J, Kolodner K, Brooner R, Kidorf M. A comparison of 1-year substance abuse treatment outcomes in community syringe exchange participants versus other referrals. Drug Alcohol Depend. 2008;97(1–2):122–9.PubMedPubMedCentralCrossRef

48.

Fox AD, Chamberlain A, Frost T, Cunningham CO. Harm reduction agencies as a potential site for buprenorphine treatment. Subst Abus. 2015;36(2):155–60.PubMedPubMedCentralCrossRef

49.

Epstein H, Perez-Correa A, Beltre J, Fitzsimmons C, Marcus P, Ramirez F, et al. Interest in long-acting injectable buprenorphine among syringe services program participants. J Opioid Manag. 2021;17(7):59–67.PubMedCrossRef

50.

Frost T, Deutsch S, Brown S, Lemien E, Cunningham CO, Fox AD. “We’ll be able to take care of ourselves”—a qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs. Subst Abus. 2021;42(4):983–9.PubMedPubMedCentralCrossRef

51.

Jakubowski A, Rath C, Harocopos A, Wright M, Kattan J, Fox AD. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation. Harm Reduct J. 2021. https://doi.org/10.1186/s12954-022-00654-0.CrossRef

52.

Lambdin BH, Bluthenthal RN, Tookes HE, Wenger L, Morris T, LaKosky P, et al. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States. Drug Alcohol Depend. 2022;237(Feb):109504. https://doi.org/10.1016/j.drugalcdep.2022.109504.CrossRefPubMed

53.

Lambdin BH, Kan D, Kral AH. Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs. Subst Abus Treat Prev Policy. 2022;17(1):1–5. https://doi.org/10.1186/s13011-022-00483-1.CrossRef

54.

Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abus. 2019. https://doi.org/10.1080/08897077.2019.1635557.CrossRefPubMed

55.

Hill K, Nussdorf L, Mount JD, Silk R, Gross C, Sternberg D, et al. Initiation of low-threshold buprenorphine in nontreatment seeking patients with opioid use disorder engaged in Hepatitis C treatment. J Addict Med. 2022;16(1):10–7.PubMedPubMedCentralCrossRef

56.

Jakubowski A, Norton BL, Hayes BT, Gibson BE, Fitzsimmons C, Stern LS, et al. Low-threshold buprenorphine treatment in a syringe services program: program description and outcomes. J Addict Med. 2021. https://doi.org/10.1097/ADM.0000000000000934.CrossRefPubMedPubMedCentral

57.

Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus. 2018;39(2):167–72. https://doi.org/10.1080/08897077.2018.1443541.CrossRefPubMedPubMedCentral

58.

Rosenthal ES, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, et al. Concurrent initiation of Hepatitis C and opioid use disorder treatment in people who inject drugs. Clin Infect Dis. 2020;71(7):1715–22.PubMedPubMedCentralCrossRef

59.

Hill K, Nussdorf L, Mount JD, Silk R, Gross C, Sternberg D, et al. Initiation of low-threshold buprenorphine in nontreatment seeking patients with opioid use disorder engaged in hepatitis c treatment. J Addict Med. 2021. https://doi.org/10.1097/ADM.0000000000000807.CrossRefPubMedCentral

60.

Chueng TA, Tookes HE, McLaughlin M, Arcaro-Vinas AM, Serota DP, Bartholomew TS. Injection and sexual behavior profiles among people who inject drugs in Miami, Florida. Subst Use Misuse. 2022;57(9):1374–82. https://doi.org/10.1080/10826084.2022.2083171.CrossRefPubMedPubMedCentral

61.

Thakarar K, Sankar N, Murray K, Lucas FL, Burris D, Smith RP. Injections and infections: understanding syringe service program utilization in a rural state. Harm Reduct J. 2021;18(1):1–8. https://doi.org/10.1186/s12954-021-00524-1.CrossRef

62.

Timko C, Schultz NR, Cucciare MA, Vittorio L, Sciences B, Arkansas C, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.PubMedCrossRef

63.

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD002207.pub4.CrossRefPubMed

64.

Moise N, Wainberg M, Shah RN. Primary care and mental health: where do we go from here? World J Psychiatry. 2021;11(7):271–6.PubMedPubMedCentralCrossRef

65.

Higashi RT, Jain MK, Quirk L, Rich NE, Waljee AK, Turner BJ, et al. Patient and provider-level barriers to hepatitis C screening and linkage to care: a mixed-methods evaluation. J Viral Hepat. 2020;27(7):680.PubMedPubMedCentralCrossRef

66.

Perez-Correa A, Abbas B, Riback L, Ghiroli M, Norton B, Murphy S, et al. Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: design and rationale. Contemp Clin Trials. 2022. https://doi.org/10.1016/j.cct.2021.106674.CrossRefPubMedPubMedCentral

67.

D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA J Am Med Assoc. 2015;313(16):1636–44. https://doi.org/10.1001/jama.2015.3474.CrossRef

68.

Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–76.PubMedPubMedCentralCrossRef

69.

21 CFR § 1306.07—Administering or dispensing of narcotic drugs. |CFR|US Law|LII/Legal Information Institute. https://www.law.cornell.edu/cfr/text/21/1306.07. Accessed 12 Sep 2022.

70.

Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, et al. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction. 2022;117(10):2635–48.PubMedCrossRef

71.

Jakubowski A, Rath C, Harocopos A, Wright M, Kattan J, Fox AD. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation. 2021. https://www.researchsquare.com. Accessed 8 Mar 2022.

72.

Hudoba M, Grenyer B, O’Toole M. Development of an enhanced needle and syringe programme: the first step programme pilot. Drug Alcohol Rev. 2004;23(3):295–7.PubMedCrossRef

73.

Kidorf M, King VL, Peirce J, Burke C, Kolodner K, Brooner RK. Psychiatric distress, risk behavior, and treatment enrollment among syringe exchange participants. Addict Behav. 2010;35(5):499–503.PubMedPubMedCentralCrossRef

74.

Havens JR, Latkin CA, Pu M, Cornelius LJ, Bishai D, Huettner S, et al. Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. J Subst Abus Treat. 2009;36(3):306–12.CrossRef

75.

Kidorf M, King VL, Peirce J, Kolodner K, Brooner RK. Benefits of concurrent syringe exchange and substance abuse treatment participation. J Subst Abus Treat. 2011;40(3):265–71.CrossRef

76.

Kuo I, Brady J, Butler C, Schwartz R, Brooner R, Vlahov D, et al. Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance. J Subst Abus Treat. 2003;24(1):67–74.CrossRef

77.

78.

Jakubowski A, Norton BL, Hayes BT, Gibson BE, Fitzsimmons C, Stern LS, et al. Low-threshold buprenorphine treatment in a syringe services program. J Addict Med. 2022;16(4):447–53.PubMedCrossRef

79.

Rosecrans A, Harris R, Saxton RE, Cotterell M, Zoltick M, Willman C, et al. Mobile low-threshold buprenorphine integrated with infectious disease services. J Subst Abus Treat. 2022;133:108553.CrossRef

80.

Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278–87.PubMedPubMedCentralCrossRef

Title: Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature
Authors: Andrea Jakubowski
Sabrina Fowler
Aaron D. Fox
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Buprenorphine
Methadone
Opioids
Opioids
Published in: Addiction Science & Clinical Practice / Issue 1/2023
Electronic ISSN: 1940-0640
DOI: https://doi.org/10.1186/s13722-023-00394-x

ERS Congress 2024

Springer Medicine

Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature

Abstract

Background

Methods

Results

Conclusions

ERS Congress 2024

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

“It feels like I’m coming to a friend’s house”: an interpretive descriptive study of an integrated care site offering iOAT (Dr. Peter Centre)

The associations between public stigma and support for others’ help-seeking for alcohol use disorder: a cross sectional study in the general Danish population

“The system always undermined what I was trying to do as an individual”: identifying opportunities to improve the delivery of opioid use services for youth from the perspective of service providers in four communities across British Columbia, Canada

Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration

“Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories

Grayken lessons: between a rock and a hard place? A 37-year-old man with acute liver injury while enrolled in a managed alcohol program for severe alcohol use disorder